MYGN Stock Recent News

NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.

NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MYRIAD GENETICS, INC. (MYGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On M.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MYRIAD GENETICS, INC. (MYGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights b.

Myriad (MYGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MYRIAD GENETICS, INC. (MYGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 6, 2025, Myriad released its first quarter 2025 financi.

Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.

Myriad Genetics, Inc. (NASDAQ:MYGN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Matt Scalo - SVP, IR Sam Raha - President & CEO Scott Leffler - CFO Mark Verratti - COO Conference Call Participants Doug Schenkel - Wolfe Research Puneet Souda - Leerink Partners David Westenberg - Piper Sandler Tejas Sawant - Morgan Stanley Sung Ji Nam - Scotiabank Andrew Cooper - Raymond James Tycho Peterson - Jefferies Lu Li - UBS Operator Welcome to the Myriad Genetics First Quarter 2025 Financial Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Matt Scalo, Senior Vice President of Investor Relations.

While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Myriad Genetics (MYGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.01 per share a year ago.